Skip to main content

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01)

Open
  • Protocol code: D9802C00001
  • EudraCT code: 2023-508276-11
  • Research group: Biomedical Research in Digestive Tract Tumors
  • Service: Oncology
  • Principal investigator:  Acosta Eyzaguirre, Daniel
  • Pathology: Tumors
  • Phase: Fase III
  • Status: Recruiting volunteers